Living with sickle cell disease means navigating a complex condition that affects the blood and multiple organs throughout the body. Modern medicine offers both established treatments to manage symptoms and groundbreaking therapies being tested in clinical trials that may transform how this inherited disorder is approached.

Understanding Treatment Goals in Sickle Cell Disease

When someone is diagnosed with sickle cell disease, treatment focuses on several important goals. The first priority is to prevent or reduce painful episodes, often called sickle cell crises, which occur when abnormally shaped red blood cells block blood vessels. Another key aim is to lower the risk of serious complications like infections, strokes, and organ damage that can develop over time. Treatment also works to manage anemia, the shortage of healthy red blood cells that causes fatigue and weakness.^[1]

The approach to treating sickle cell disease varies from person to person. Doctors consider the specific type of sickle cell disease, the severity of symptoms, the patient’s age, and how the disease has affected their body so far. Some people with milder forms may need less intensive treatment, while others with more severe disease require comprehensive medical care throughout their lives. What works well for one patient might not be the best choice for another, which is why individualized care plans are so important.^[2]

There are two main categories of treatment available today. The first includes standard therapies that have been approved by medical societies and used successfully for years. These treatments help prevent complications and manage symptoms when they occur. The second category involves experimental therapies being studied in clinical trials. These research studies test new drugs and innovative approaches that might offer better outcomes or even potential cures for some patients. Participating in clinical trials gives certain patients access to cutting-edge treatments before they become widely available.^[4]

Standard Treatment Approaches

The cornerstone of standard treatment for sickle cell disease is a medicine called hydroxyurea, also known by the brand names Droxia and Hydrea. This drug was the first medication approved specifically for sickle cell disease back in 1998, and it remains the primary treatment option today. Hydroxyurea works by increasing the production of fetal hemoglobin, a type of hemoglobin that babies have before birth. Fetal hemoglobin doesn’t sickle like the abnormal hemoglobin found in sickle cell disease, so having more of it helps red blood cells stay round and flexible.^[10]

Studies have shown that hydroxyurea significantly reduces the frequency of painful crises. Patients taking this medicine also need fewer blood transfusions and experience fewer episodes of acute chest syndrome, a dangerous lung complication. The National Heart, Lung and Blood Institute recommends that doctors consider starting hydroxyurea in children as young as nine months old, and the medication is FDA-approved for children aged two and older. Adults benefit from it as well.^[10][11]

Like all medications, hydroxyurea can cause side effects. Because it affects blood cell production, patients taking hydroxyurea need regular blood tests to monitor their white blood cell and platelet counts. The drug can lower these counts, which might increase infection risk or affect blood clotting. However, for most patients, the benefits of reduced pain and fewer complications outweigh these risks. Doctors carefully monitor patients and adjust doses as needed.^[11]

Another important medication is L-glutamine, sold under the brand name Endari. The FDA approved this drug in 2017 for patients five years and older. L-glutamine is an amino acid that acts as an antioxidant, helping to protect red blood cells from damage. It comes as a powder that patients can mix with water or food, making it relatively easy to take. Clinical trials showed that L-glutamine reduces the number of pain crises and hospitalizations.^[12][10]

Crizanlizumab, marketed as Adakveo, represents another treatment option that received FDA approval in 2019. This medication is given as an intravenous infusion once a month after an initial loading dose. It works by blocking a protein called P-selectin, which plays a role in the process that causes red blood cells to stick together and to the walls of blood vessels. By preventing this sticking, crizanlizumab helps keep blood flowing more smoothly and reduces the frequency of painful vaso-occlusive crises. The infusion takes about 30 minutes, and it’s approved for patients 16 years and older.^[12][15]

Beyond medications that modify the disease, many treatments focus on preventing complications. Patients with sickle cell disease are more vulnerable to infections because the disease often damages the spleen, an organ that helps fight germs. To protect against infections, most people with sickle cell disease take daily antibiotics, usually penicillin, often starting in infancy and continuing throughout life. This simple measure dramatically reduces the risk of severe bacterial infections, especially in young children.^[13][10]

Vaccinations are equally critical for infection prevention. All patients should receive routine childhood vaccines, but they also need additional immunizations that aren’t standard for the general population. These include vaccines against pneumococcal bacteria, meningococcal disease, and yearly influenza vaccines. Because infections can trigger sickle cell crises and quickly become life-threatening, staying up to date on vaccinations is essential.^[17][13]

Another key component of standard care involves folic acid supplementation. The body uses folic acid to make new red blood cells. Because people with sickle cell disease destroy red blood cells more rapidly than healthy individuals, they need extra folic acid to keep up with the increased demand for new cell production. Taking folic acid supplements daily helps prevent the anemia from becoming worse.^[12]

Blood transfusions play an important role in managing both acute complications and preventing future problems. In an emergency, such as when severe anemia develops or during a life-threatening complication, transfusions can be lifesaving by quickly increasing the number of healthy red blood cells. Some patients receive regular transfusions on a scheduled basis to prevent strokes or to manage severe, chronic symptoms. These scheduled transfusions, sometimes given every few weeks, help keep the percentage of sickled cells low. However, frequent transfusions can lead to iron overload in the body over time, which may require additional treatment to remove excess iron.^[10][11]

Pain management is another crucial aspect of standard care. When painful crises occur, they can range from mild discomfort to severe, debilitating pain requiring hospitalization. For mild to moderate pain, over-the-counter medications like acetaminophen or ibuprofen may be sufficient. More severe pain often requires prescription opioid medications such as morphine. Healthcare providers emphasize the importance of treating pain quickly and aggressively. Guidelines recommend that patients arriving at emergency departments with sickle cell pain should receive pain medication within 30 minutes of being seen, as prompt pain control can shorten hospital stays and improve outcomes.^[15][13]

The duration of these standard treatments varies. Disease-modifying medications like hydroxyurea, L-glutamine, and crizanlizumab are typically taken continuously, as long as they’re helping and not causing unacceptable side effects. Antibiotics for infection prevention often continue lifelong. Blood transfusions might be needed just once in an emergency, or they might become a regular part of treatment for years. Each person’s treatment plan evolves over time based on how well therapies are working and what complications develop.^[10]

Breakthrough Therapies in Clinical Trials

The landscape of sickle cell disease treatment is being transformed by innovative therapies currently being tested in clinical research studies. These experimental approaches represent hope for better symptom control and, in some cases, potential cures. Clinical trials progress through several phases. Phase I trials primarily test whether a new treatment is safe and determine the appropriate dose. Phase II trials assess whether the treatment actually works to improve the disease. Phase III trials compare the new treatment to existing standard therapies in larger groups of patients to confirm effectiveness and monitor for less common side effects.^[14]

One of the most exciting developments in recent years has been the approval of gene therapy approaches for sickle cell disease. In December 2023, the U.S. Food and Drug Administration approved two gene therapies that represent transformative treatment options. These therapies work at the genetic level to address the root cause of sickle cell disease rather than just managing symptoms.^[10]

The first gene therapy approach, known as exagamglogene autotemcel (marketed as Casgevy), uses a technology called CRISPR gene editing. This technique actually modifies the patient’s own genetic material. Here’s how it works: doctors collect stem cells from the patient’s bone marrow. Scientists then use CRISPR technology to edit a specific gene in those cells that controls fetal hemoglobin production. Remember, fetal hemoglobin doesn’t sickle. By editing this gene, the modified cells produce high levels of fetal hemoglobin. The patient then receives chemotherapy to clear out their existing bone marrow stem cells, and the edited cells are infused back into their body. These modified cells take up residence in the bone marrow and begin producing red blood cells that contain high amounts of fetal hemoglobin, reducing or eliminating sickling.^[12][14]

The second approved gene therapy, lovotibeglogene autotemcel (sold as Lyfgenia), takes a different approach. Instead of editing an existing gene, this therapy adds a modified gene into the patient’s cells. Scientists extract stem cells from the patient, then use a disabled virus to deliver a new, functional gene that can produce anti-sickling hemoglobin. After the patient receives chemotherapy to prepare their bone marrow, these genetically modified stem cells are returned to their body. The new gene allows the cells to produce hemoglobin that works properly, reducing sickling and its complications.^[12][14]

Early results from gene therapy trials have been remarkable. Many patients who received these treatments experienced dramatic reductions in pain crises and hospitalizations. Some achieved what doctors call a “functional cure,” meaning they no longer experience the typical symptoms and complications of sickle cell disease, though the underlying genetic mutation is still present in some of their cells. These therapies are currently very expensive and require specialized medical centers with expertise in performing them, which limits access. They also involve significant risks, including the intensive chemotherapy required beforehand and potential complications from the procedure itself.^[14]

Clinical trials are also investigating another potentially curative approach: hematopoietic stem cell transplantation, commonly called bone marrow transplant. This procedure replaces the patient’s faulty blood-forming stem cells with healthy ones from a donor. When successful, the transplanted cells establish themselves in the bone marrow and begin producing normal red blood cells, effectively curing the disease. The challenge has always been finding a well-matched donor, typically a sibling, and managing the risks of the procedure, including graft-versus-host disease, where the donor cells attack the recipient’s body.^[4][13]

Researchers are working on ways to make stem cell transplantation safer and more widely available. Some trials are testing less intense conditioning regimens—milder forms of chemotherapy given before the transplant—to reduce side effects. Others are exploring the use of partially matched donors or even adult volunteer donors when family members aren’t suitable matches. These advances could make this curative option available to more patients who might benefit from it.^[14]

Beyond curative therapies, numerous clinical trials are testing drugs designed to reduce specific complications of sickle cell disease. For example, researchers are studying medications that might prevent or treat pulmonary hypertension, a serious condition where high blood pressure develops in the lungs. Other trials are investigating treatments for chronic pain, kidney disease, and leg ulcers—all common long-term complications of sickle cell disease.^[14]

Some experimental therapies focus on preventing the sickling process itself through different mechanisms than existing drugs. Scientists are testing compounds that help hemoglobin hold onto oxygen better, making it less likely to polymerize and cause cells to sickle. Others are investigating drugs that make red blood cells less sticky or that reduce inflammation in blood vessels, which contributes to vaso-occlusive crises.^[14]

Clinical trials for sickle cell disease are being conducted at specialized centers around the world, including locations in the United States, Europe, Africa, and other regions. Patient eligibility varies by study. Some trials are looking for patients with severe disease who have failed multiple standard treatments. Others seek patients with milder disease or specific types of sickle cell disease. Age restrictions differ among studies—some enroll only adults, while others include children or adolescents. Participants in clinical trials often receive the experimental treatment at no cost and benefit from close medical monitoring, though they must also accept the uncertainties that come with testing new therapies.^[4][14]

Most common treatment methods

• Disease-modifying medications
  • Hydroxyurea increases fetal hemoglobin production to reduce sickling and decrease pain crises, approved since 1998
  • L-glutamine (Endari) provides antioxidant protection to red blood cells, approved for patients five years and older
  • Crizanlizumab (Adakveo) blocks P-selectin to prevent blood cells from sticking together, given as monthly infusions
• Infection prevention
  • Daily penicillin antibiotics to reduce risk of bacterial infections, especially in children
  • Vaccination against pneumococcal bacteria, meningococcal disease, and annual influenza
  • Prompt treatment of fevers and infections to prevent serious complications
• Blood transfusions
  • Emergency transfusions for acute complications like severe anemia or stroke
  • Regular scheduled transfusions to prevent stroke in high-risk patients
  • Exchange transfusions to reduce the percentage of sickled cells in severe cases
• Pain management
  • Over-the-counter medications like acetaminophen and ibuprofen for mild to moderate pain
  • Prescription opioids such as morphine for severe pain crises
  • Non-medication approaches including heating pads, warm baths, and physical therapy
• Gene therapy
  • Exagamglogene autotemcel (Casgevy) uses CRISPR technology to edit genes and increase fetal hemoglobin
  • Lovotibeglogene autotemcel (Lyfgenia) adds a functional gene to produce anti-sickling hemoglobin
  • Both therapies approved in December 2023 as potentially transformative treatments
• Stem cell transplantation
  • Bone marrow transplant from matched donor can cure sickle cell disease
  • Requires intensive chemotherapy preparation and carries risk of graft-versus-host disease
  • Research ongoing to make procedure safer and more widely available
• Supportive care
  • Folic acid supplementation to support increased red blood cell production
  • Hydration and avoiding triggers like extreme temperatures and dehydration
  • Regular medical monitoring and preventive screening for complications